Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 May 31;58(5):729–735. doi: 10.1002/pbc.23157

Figure 1.

Figure 1

Responses of sarcoma xenografts to IMC-A12 and rapamycin administered as single agents or in combination. Tumor-bearing mice were treated with IMC-A12 by IP administration at a dose of 1 mg per mouse administered twice weekly, and rapamycin by intraperitoneal (IP) administration at 5 mg/kg daily × 5 repeated weekly for a planned four consecutive weeks.

Left panels: Kaplan-Meier Event-Free Survival estimates for control and treated groups. Control (_____); IMC-A12 ( Inline graphic); Rapamycin ( Inline graphic); IMC-A12 + rapamycin ( Inline graphic). Center panels: Individual tumor growth curves. Controls (gray), IMC-A12 treated (black). Right panels: Individual tumor growth curves. Rapamycin (gray), IMC-A12 + rapamycin (black).